Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lucie Ellis

Managing Editor, In Vivo

London, UK
Lucie Ellis has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Managing Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo’s print and online editions and also contributes feature-length articles to the publication on the topics of leadership, R&D, innovation and more.
Advertisement
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

One For All Not All For One With Personalized Therapies

Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect. 

Personalized Medicine Research and Development Strategies

C-Suite Snippets: Genomic Medicine Is Coming Of Age

In case you missed it: catch up with snippets from interviews published by In Vivo this week. 

Business Strategies Innovation

European Life Science Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared with the $686m companies raised in 2018 overall. Experts says this "rude health" should continue for the next two to three years, at least.

Europe Financing

European Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.

Business Strategies Commercial

C-Suite Snippets: Planning For The Future Cancer Market

In case you missed it: catch up with snippets from interviews published by In Vivo this week.

Market Access Research and Development Strategies

VC Playbook: Making Focus A Strategic Advantage

In this latest installment of In Vivo’s VC Playbook series, Robert Tansley, a partner at Cambridge Innovation Capital, explains the fund’s special arrangement in Cambridge, UK and how the young venture capital group expects to grow in the biotech sector – the imminent prospect of Brexit notwithstanding.

VC Playbook Strategy
See All
Advertisement
UsernamePublicRestriction

Register